enGene Holdings Inc. (ENGN)

Market Cap	390.59M
Revenue (ttm)	n/a
Net Income (ttm)	-94.72M
Shares Out	51.19M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,780
Open	7.68
Previous Close	7.75
Day's Range	7.19 - 7.81
52-Week Range	2.65 - 11.00
Beta	-0.26
Analysts	Buy
Price Target	20.29 (+165.92%)
Earnings Date	Sep 11, 2025

About ENGN

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 57
• Stock Exchange: NASDAQ
• Ticker Symbol: ENGN
• Website: https://www.engene.com

Analyst Summary

According to 7 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $20.29, which is an increase of 165.92% from the latest price.

Price Target

$20.29

(165.92% upside)

Analyst Consensus: Buy